Health problem addressed

Every year 1 million babies die during childbirth. Complications during childbirth kill half a million mothers, and a further 1 million babies within a month of birth. Over 99% of these deaths occur in the developing world and many are preventable with timely detection of complications.

Product description

Using advanced Doppler ultrasound technology the monitor detects and measures the fetal heart rate. This vital indicator of fetal stress allows rural healthcare workers to make life-saving decisions during childbirth. Destined for use in low resource settings, its design focuses on simplicity of use, durability and electrical power independence.

Product functionality

The fetal heart rate monitor is designed for ruggedness and simplicity of use, but its most distinguishing element is the human-powered electricity solution. By using the well-proven self-powered technology, simply winding a handle will charge the batteries. Each minute of winding provides about 10 minutes of monitoring time.

Developer’s claims of product benefits

Fetal monitoring methods in low income countries are limited to Pinard fetal stethoscopes. Current availability of monitoring in the majority of primary and district care facilities in middle and especially low income countries being limited makes this monitoring unreliable. The accuracy of the Pinard is without much evidence indicating improved outcomes in situations of fetal distress. Doppler ultrasound fetal heart rate monitors are recommended but only 1% of these devices worldwide are available in low income countries. Our device aims at a reduction in perinatal mortality and neonatal encephalopathy.

Operating steps

The powerful narrow beam Doppler head is placed on a pregnant woman’s abdomen. The fetal heart rate is delivered as an audio signal and displayed as a number in beats per minute.

Development stage

Our fetal heart rate monitor won the Index Global Design Award in 2009 and has the potential to dramatically improve health outcomes especially for babies. Pilot field testing was carried out in 9 South African primary care maternity facilities run only by midwives (without doctors). The majority of the midwives who used the monitor preferred it to the Pinard as the device was easy to charge; it was very easy to obtain a reading and quick to identify the fetal heart rate within 30 seconds.

Future work and challenges

The fetal heart rate monitor is currently available and in production.

Use and maintenance

User: Nurse, midwife, physician.
Training: none.
Maintenance: Technician

Environment of use

Setting: Rural. Primary and secondary health care facilities.
Requirements: none.

Product specifications

Dimensions (mm): 170 x 85 x 75
Weight (kg): 0.7
Consumables: none.
Life time: 5 years
Shelf life: 3 years

List price (USD): 350
Other features: Portable and reusable. Runs on batteries. Uses software.
Year of commercialization: 2010
Currently sold in: United Kingdom, South Africa and other African countries.

Contact details
James Briaris
Email: james.briaris@gmail.com
Telephone: +44 7595 943 259
Fax: -
Disclaimer

Eligibility for inclusion in the compendium has been evaluated by EuroScan member agencies and WHO. However, the evaluation by EuroScan member agencies and WHO has been solely based on a limited assessment of data and information submitted in the developers’ applications and, where available, of additional sources of evidence, such as literature search results or other publicly available information. There has been no rigorous review for safety, efficacy, quality, applicability, nor cost acceptability of any of the technologies. Therefore, inclusion in the compendium does not constitute a warranty of the fitness of any technology for a particular purpose. Besides, the responsibility for the quality, safety and efficacy of each technology remains with the developer and/or manufacturer. The decision to include a particular technology in the compendium is subject to change on the basis of new information that may subsequently become available to WHO. WHO will not be held to endorse nor to recommend any technology included in the compendium. Inclusion in the compendium solely aims at drawing stakeholders’ attention to innovative health technologies, either existing or under development, with a view to fostering the development and availability of, and/or access to, new and emerging technologies which are likely to be accessible, appropriate and affordable for use in low- and middle-income countries.

WHO does not furthermore warrant or represent that:

1. the list of new and emerging health technologies is exhaustive or error free; and/or that
2. the technologies which are included in the compendium will be embodied in future editions of the compendium; and/or that
3. the use of the technologies listed is, or will be, in accordance with the national laws and regulations of any country, including but not limited to patent laws; and/or that
4. any product that may be developed from the listed technologies will be successfully commercialized in target countries or that WHO will finance or otherwise support the development or commercialization of any such product.

WHO disclaims any and all liability and responsibility whatsoever for any injury, death, loss, damage or other prejudice of any kind whatsoever that may arise as a result of, or in connection with, the procurement, distribution and/or use of any technology embodied in the compendium, or of any resulting product and any future development thereof.